Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADMA

ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

5.26USD+0.08 (+1.54%)Market Closed
Watchlist

Market Summary

USD5.26+0.08
Market Closed
1.54%

ADMA Stock Price

View Fullscreen

ADMA RSI Chart

ADMA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-52.07

Price/Sales (Trailing)

5.07

EV/EBITDA

74.38

Price/Free Cashflow

-50.58

ADMA Price/Sales (Trailing)

ADMA Profitability

Operating Margin

30.74%

EBT Margin

-7.67%

Return on Equity

-15.07%

Return on Assets

-6.54%

Free Cashflow Yield

-1.98%

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

234.3M

Rev. Growth (Yr)

63.72%

Rev. Growth (Qtr)

11.89%

ADMA Earnings

Earnings (TTM)

-22.8M

Earnings Growth (Yr)

117.22%

Earnings Growth (Qtr)

140.26%

Breaking Down ADMA Revenue

Last 7 days

0.8%

Last 30 days

5.8%

Last 90 days

33%

Trailing 12 Months

47.5%

How does ADMA drawdown profile look like?

ADMA Financial Health

Current Ratio

6.54

ADMA Investor Care

Shares Dilution (1Y)

14.83%

Diluted EPS (TTM)

-0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023181.9M208.1M234.3M0
2022122.6M138.7M159.1M154.1M
202148.1M58.1M68.5M109.6M
202036.2M37.0M40.1M42.2M
201916.5M18.8M21.8M29.6M
201824.2M25.4M24.9M17.0M
201711.2M12.3M14.1M22.8M
20167.8M8.8M9.8M10.7M
20155.9M5.7M6.2M7.2M
20143.8M4.6M4.9M5.9M
20131.9M2.4M3.2M3.1M
20121.7M1.5M1.3M1.1M
20110001.9M
20100000

Tracking the Latest Insider Buys and Sells of ADMA Biologics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 31, 2023
grossman adam s
sold (taxes)
-104,218
4.52
-23,057
president and ceo
Dec 31, 2023
lenz brian
sold (taxes)
-76,424
4.52
-16,908
evp, cfo
Sep 30, 2023
lenz brian
sold (taxes)
-54,659
3.58
-15,268
evp, cfo
Sep 30, 2023
grossman adam s
sold (taxes)
-67,010
3.58
-18,718
president and ceo
Aug 30, 2023
grossman jerrold b
bought
482,144
3.7088
130,000
-
Aug 24, 2023
kwon young
bought
97,500
3.9
25,000
-
Aug 22, 2023
fong bryant
sold
-5,544,740
3.8685
-1,433,300
-
Aug 18, 2023
grossman adam s
sold
-1,038,350
4.1534
-250,000
president and ceo
Aug 16, 2023
grossman adam s
sold
-13.155
4.385
-3.00
president and ceo
Aug 16, 2023
lenz brian
sold
-793,400
4.4527
-178,184
evp, cfo

1–10 of 50

Which funds bought or sold ADMA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-93.1
-791,000
76,000
0.01%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
11.48
70,000
242,000
-%
Feb 16, 2024
Spouting Rock Asset Management, LLC
new
-
83,163
83,163
0.03%
Feb 15, 2024
MERCER GLOBAL ADVISORS INC /ADV
reduced
-1.27
14,000
70,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
80.9
392,723
698,584
-%
Feb 15, 2024
GTS SECURITIES LLC
sold off
-100
-37,844
-
-%
Feb 15, 2024
BARCLAYS PLC
added
44.27
1,184,000
2,625,000
-%
Feb 15, 2024
TOWNSQUARE CAPITAL LLC
new
-
150,426
150,426
-%
Feb 15, 2024
Virtus Fund Advisers, LLC
unchanged
-
11,495
55,271
0.34%
Feb 15, 2024
Virtus Investment Advisers, Inc.
added
115
449,887
710,851
0.53%

1–10 of 46

Are Funds Buying or Selling ADMA?

Are funds buying ADMA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADMA
No. of Funds

Unveiling ADMA Biologics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nuveen asset management, llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
teachers advisors, llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
tiaa cref investment management llc
2.24%
5,062,545
SC 13G
Feb 14, 2024
perceptive advisors llc
2.8%
6,433,369
SC 13G/A
Feb 13, 2024
vanguard group inc
5.71%
12,891,875
SC 13G
Jan 26, 2024
blackrock inc.
7.9%
17,917,745
SC 13G/A
Feb 14, 2023
nuveen asset management, llc
2.48%
5,483,369
SC 13G/A
Feb 14, 2023
teachers advisors, llc
2.48%
5,483,369
SC 13G/A
Feb 14, 2023
tiaa cref investment management llc
2.48%
5,483,369
SC 13G/A
Feb 14, 2023
perceptive advisors llc
5.4%
11,900,255
SC 13G/A

Recent SEC filings of ADMA Biologics Inc

View All Filings
Date Filed Form Type Document
Feb 21, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Jan 08, 2024
8-K
Current Report
Jan 05, 2024
4
Insider Trading

Peers (Alternatives to ADMA Biologics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
5.8B
107.9M
-3.85% 226.12%
-9.38
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ADMA Biologics Inc News

Latest updates
Yahoo Canada Finance28 hours ago
Seeking Alpha19 Jan 202408:00 am

ADMA Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue11.9%67,27560,12356,91449,98141,09033,90529,10355,00020,68117,83116,04913,95610,2767,78810,20011,8187,2237,0003,5294,0564,230
Cost Of Revenue-1.9%42,62243,43340,40135,80431,43326,13625,44122,87120,29518,83317,77019,11111,85513,49616,82911,6927,91610,4919,40511,1429,164
Gross Profit47.7%24,65316,69016,51314,1779,6577,7693,6623,511385-1,002-1,721----------
Operating Expenses-7.0%15,96717,16317,32620,23618,97316,94418,47716,70314,82214,57913,443-30,11524,07724,91126,97019,86416,27317,90016,73720,60418,022
  S&GA Expenses3.4%14,72614,24814,51213,89512,89311,97013,70011,69810,72710,43810,0349,3009,1168,7037,9327,0327,1976,0865,5956,0735,670
  R&D Expenses-57.5%5961,4038551,0741,0428736247297711,1599881,0131,7081,6561,5294654915178719171,003
EBITDA Margin-4.4%0.06*0.07*0.06*0.05*0.04*0.02*0.01*0.01*0.00*-0.01*-0.02*-0.05*-0.07*--------
Interest Expenses1.6%6,3986,2996,1155,7375,5804,5733,3893,3163,2993,2473,1963,1093,0913,0672,7172,7312,6492,0731,5411,4381,402
EBT Margin11.2%-0.08*-0.09*-0.10*-0.12*-0.11*-0.13*-0.15*-0.16*-0.26*-0.31*-0.37*-0.43*-0.45*--------
Net Income140.3%2,565-6,370-6,788-12,231-14,899-13,764-25,007-16,649-17,712-18,905-18,379-19,407-16,917-20,178-19,245-10,561-11,438-13,211-13,067-18,037-15,135
Net Income Margin49.7%-0.10*-0.19*-0.26*-0.43*-0.44*-0.53*-0.64*-0.65*-1.09*-1.27*-1.56*-1.79*-1.67*--------
Free Cashflow262.0%11,229-6,931-16,666-11,127-16,665-16,770-28,855-37,141-16,201-36,737-35,800-35,817-26,737--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets1.7%34934334134830129730827623923323620819019221112713814378.0089.00106
  Current Assets2.8%27426626427022422324020917517117715414014316586.0097.0010438.0045.0063.00
    Cash Equivalents18.6%74.0063.0069.0087.0035.0052.0070.0051.0034.0042.0062.0056.0060.0076.0010127.0048.0074.0017.0027.0046.00
  Inventory0.8%16316216416316314613912511410094.0082.0070.0056.0052.0053.0040.0024.0018.0019.0014.00
  Net PPE-2.6%55.0056.0057.0058.0057.0055.0053.0051.0048.0046.0044.0042.0040.0037.0035.0032.0031.0029.0030.0030.0030.00
  Goodwill0%4.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.004.00
Liabilities0.7%19819619519620018318113513612112311911911511410110296.0068.0069.0069.00
  Current Liabilities-0.3%42.0042.0037.0039.0044.0028.0032.0030.0032.0018.0021.0020.0016.0013.0014.0014.0015.0010.008.0010.0010.00
  Long Term Debt--------------------3.003.00
Shareholder's Equity3.2%15114714615210011412714110311211388.0071.0077.0096.0026.0036.0047.0010.0020.0037.00
  Retained Earnings0.5%-488-491-484-478-465-450-437-412-395-377-358-340-321-304-283-264-254-242-229-216-198
  Additional Paid-In Capital0.3%640638630630566565564553498489471429392381380291290290240236236
Shares Outstanding0.6%22622522222219619619619613412711610588.00--------
Float------373---173---184-------
Cashflow (Last 12 Months)
(In )
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations297.8%11,985,078-6,058,756-14,722,274-7,379,315-13,284,761-12,830,768-26,013,413-33,465,232-13,412,387-32,262,237-33,229,126-32,219,436-23,852,087-21,284,475-24,646,960-19,652,036-23,630,332-18,623,952-14,287,184-18,793,124-12,543,405
  Share Based Compensation3.5%1,694,6411,637,0381,110,1661,068,6021,313,4941,191,0471,641,3881,213,393688,274805,189781,397688,182774,784715,608676,548636,108650,670726,736637,263595,532577,581
Cashflow From Investing13.3%-756,557-872,633-1,944,596-3,748,521-3,380,481-3,940,084-2,842,085-3,675,854-2,788,669-4,475,574-2,571,161-3,598,321-2,885,075-4,168,408-2,072,876-1,594,296-1,971,867-135,222-110,453-819,006-230,219
Cashflow From Financing73.0%415,355240,115-650,50962,743,358-843,791-319,04147,271,32653,819,6348,202,66817,181,06041,844,84432,063,86410,631,085-1,694101,203,400-7,685-7,55875,840,8054,177,063-507-12,862
  Buy Backs----------------------859

ADMA Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]    
Revenues$ 67,274,598$ 41,090,137$ 184,311,323$ 104,098,237
Cost of product revenue42,622,01331,433,496126,455,74583,010,156
Gross profit24,652,5859,656,64157,855,57821,088,081
OPERATING EXPENSES:    
Research and development595,9031,041,9472,854,5142,539,444
Plasma center operating expenses466,8984,859,4503,580,78512,755,525
Amortization of intangible assets178,838178,838536,514536,514
Selling, general and administrative14,725,78712,893,13943,485,00138,563,136
Total operating expenses15,967,42618,973,37450,456,81454,394,619
INCOME (LOSS) FROM OPERATIONS8,685,159(9,316,733)7,398,764(33,306,538)
OTHER INCOME (EXPENSE):    
Interest income423,2767,2361,004,55142,573
Interest expense(6,397,553)(5,580,366)(18,812,144)(13,542,419)
Loss on extinguishment of debt000(6,669,941)
Other expense(145,827)(9,641)(185,638)(195,942)
Other expense, net(6,120,104)(5,582,771)(17,993,231)(20,365,729)
NET INCOME (LOSS)$ 2,565,055$ (14,899,504)$ (10,594,467)$ (53,672,267)
BASIC INCOME (LOSS) PER COMMON SHARE (in dollars per share)$ 0.01$ (0.08)$ (0.05)$ (0.27)
DILUTED INCOME (LOSS) PER COMMON SHARE (in dollars per share)$ 0.01$ (0.08)$ (0.05)$ (0.27)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (in shares)225,276,980196,383,935223,306,331196,204,893
Diluted (in shares)233,761,262196,383,935223,306,331196,204,893

ADMA Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 74,156,765$ 86,521,542
Accounts receivable, net31,318,68015,505,048
Inventories163,116,105163,280,047
Prepaid expenses and other current assets5,107,4555,095,146
Total current assets273,699,005270,401,783
Property and equipment, net54,814,60758,261,481
Intangible assets, net476,9021,013,415
Goodwill3,529,5093,529,509
Right-to-use assets9,753,72510,485,447
Deposits and other assets6,722,8174,770,246
TOTAL ASSETS348,996,565348,461,881
Current liabilities:  
Accounts payable10,851,44613,229,390
Accrued expenses and other current liabilities29,863,72624,989,349
Current portion of deferred revenue142,834142,834
Current portion of lease obligations982,891905,369
Total current liabilities41,840,89739,266,942
Senior notes payable, net of discount142,025,542142,833,063
Deferred revenue, net of current portion1,725,9061,833,031
End of term fee1,567,1391,500,000
Lease obligations, net of current portion9,965,08810,704,176
Other non-current liabilities434,647350,454
TOTAL LIABILITIES197,559,219196,487,666
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY  
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding00
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 225,958,084 and 221,816,930 shares issued and outstanding22,59622,182
Additional paid-in capital640,025,888629,968,704
Accumulated deficit(488,611,138)(478,016,671)
TOTAL STOCKHOLDERS' EQUITY151,437,346151,974,215
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 348,996,565$ 348,461,881
ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
 CEO
 WEBSITEwww.admabiologics.com
 EMPLOYEES617

ADMA Biologics Inc Frequently Asked Questions


What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Wed Feb 21 2024, market cap of ADMA Biologics Inc is 1.17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers. The fair value of ADMA Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ADMA Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, ADMA's PE ratio (Price to Earnings) is -51.28 and Price to Sales (PS) ratio is 5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided -0.046 (multiply by 100 for percentage) rate of return.